CLOMIPHENE-25MGOther abnormal uterine and vaginal bleeding
How does the disease interact with Ofort 25mg Tablet:
Abnormal uterine bleeding:
In patients who are not diagnosed with abnormal genital bleeding, Ofort 25mg Tablet is contraindicated. Evaluate the patients for the presence of neoplastic lesions.
How to manage the interaction:
The use of Ofort 25mg Tablet is contraindicated in patients with undiagnosed, abnormal genital bleeding.
CLOMIPHENE-25MGHepatic failure, not elsewhere classified
How does the disease interact with Ofort 25mg Tablet:
Hepatic dysfunction:
Ofort 25mg Tablet is contraindicated for patients who have liver failure or a past history of hepatic dysfunction. The Ofort 25mg Tablet is primarily metabolized in the liver and enters into enterohepatic circulation. Thus, there will be increase in serum concentration and half-life of Ofort 25mg Tablet.
How to manage the interaction:
The use of Ofort 25mg Tablet is contraindicated in patients with liver disease or history of hepatic dysfunction.
CLOMIPHENE-25MGDisorders of endocrine glands in diseases classified elsewhere
How does the disease interact with Ofort 25mg Tablet:
Pituitary activity:
Ofort 25mg Tablet is contraindicated for patients who have uncontrolled thyroid or adrenal dysfunction, or who have an organic intracranial lesion such as a pituitary tumour. Ofort 25mg Tablet interacts with oestrogen receptors in several tissues, including the pituitary, causing a rise in pituitary gonadotropin secretion.
How to manage the interaction:
Ofort 25mg Tablet is contraindicated in patients with uncontrolled thyroid, adrenal dysfunction or pituitary tumour.
CLOMIPHENE-25MGOther disorders of adrenal gland
How does the disease interact with Ofort 25mg Tablet:
Uncontrolled adrenal dysfunction :
Ofort 25mg Tablet is contraindicated in patients with uncontrolled adrenal function. Adrenal dysfunction can make pregnancy difficult. Ofort 25mg Tablet therapy may cause changes in steroid production and/or fluid balance.
How to manage the interaction:
The use of Ofort 25mg Tablet is contraindicated in patients with uncontrolled adrenal function.
CLOMIPHENE-25MGDisorders of lipoprotein metabolism and other lipidaemias
How does the disease interact with Ofort 25mg Tablet:
Hyperlipidemia:
Some patients who are on Ofort 25mg Tablet therapy have reported hypertriglyceridemia. Preexisting hyperlipidemia or a family history of hyperlipidemia, Higher doses of Ofort 25mg Tablet for a long period are related to an increased risk of hypertriglyceridemia. In this conditions, Monitor plasma triglycerides regular basis and also at base line before initiating the therapy with Ofort 25mg Tablet.
How to manage the interaction:
Hypertriglyceridemia may occur during Ofort 25mg Tablet therapy, especially in patients with a family history of hyperlipidemia and use of higher than the recommended dose and/or longer duration of treatment. Periodic monitoring of plasma triglycerides is recommended in patients with preexisting or family history of hyperlipidemia. Pretreatment screening of triglyceride levels is advised in patients initiating Ofort 25mg Tablet therapy.